Search

Your search keyword '"De Wit, Stéphane"' showing total 1,343 results
Start Over Author "De Wit, Stéphane"
1,343 results on '"De Wit, Stéphane"'

1. Risk of tuberculosis after initiation of antiretroviral therapy among persons with HIV in Europe

Author

Johansen, Isik S., Roen, Ashley, Kraef, Christian, Martín-Iguacel, Raquel, Nemeth, Johannes, Fenner, Lukas, Zangerle, Robert, Llibre, Josep M., Miller, Robert F., Suarez, Isabelle, de Wit, Stephane, Wit, Ferdinand, Mussini, Christina, Saracino, Annalisa, Canetti, Diana, Volny-Anne, Alain, Jaschinski, Nadine, Neesgaard, Bastian, Ryom, Lene, Peters, Lars, Garges, Harmony P., Rooney, James F., Podlekareva, Daria, Mocroft, Amanda, and Kirk, Ole

Published
2024
Full Text
View/download PDF

3. All-cause and AIDS-related mortality among people with HIV across Europe from 2001 to 2020: impact of antiretroviral therapy, tuberculosis and regional differences in a multicentre cohort study

Author

Kraef, Christian, Tusch, Erich, Singh, Sabine, Østergaard, Lars, Fätkenheuer, Gerd, Castagna, Antonella, Moreno, Santiago, Kusejko, Katharina, Szetela, Bartosz, Kuznetsova, Anastasiia, Tomažič, Janez, Ranin, Jovan, Zangerle, Robert, Mansson, Fredrik, Marchetti, Giulia, De Wit, Stéphane, Clarke, Amanda, Gerstoft, Jan, Podlekareva, Daria, Peters, Lars, Reekie, Joanne, and Kirk, Ole

Published
2024
Full Text
View/download PDF

5. Novel role of UHRF1 in the epigenetic repression of the latent HIV-1

Author

Verdikt, Roxane, Bendoumou, Maryam, Bouchat, Sophie, Nestola, Lorena, Pasternak, Alexander O, Darcis, Gilles, Avettand-Fenoel, Véronique, Vanhulle, Caroline, Aït-Ammar, Amina, Santangelo, Marion, Plant, Estelle, Le Douce, Valentin, Delacourt, Nadège, Cicilionytė, Aurelija, Necsoi, Coca, Corazza, Francis, Passaes, Caroline Pereira Bittencourt, Schwartz, Christian, Bizet, Martin, Fuks, François, Sáez-Cirión, Asier, Rouzioux, Christine, De Wit, Stéphane, Berkhout, Ben, Gautier, Virginie, Rohr, Olivier, and Van Lint, Carine

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Genetics, HIV/AIDS, Infectious Diseases, 2.1 Biological and endogenous factors, Aetiology, 2.2 Factors relating to the physical environment, Infection, Good Health and Well Being, Acquired Immunodeficiency Syndrome, CCAAT-Enhancer-Binding Proteins, DNA Methylation, Decitabine, Epigenetic Repression, HIV Infections, HIV-1, Humans, Ubiquitin-Protein Ligases, Virus Latency, HIV-1 latency, Reactivation, UHRF1, Epigenetics, EGCG, Clinical Sciences, Public Health and Health Services, Clinical sciences, Epidemiology
Abstract

BackgroundThe multiplicity, heterogeneity, and dynamic nature of human immunodeficiency virus type-1 (HIV-1) latency mechanisms are reflected in the current lack of functional cure for HIV-1. Accordingly, all classes of latency-reversing agents (LRAs) have been reported to present variable ex vivo potencies. Here, we investigated the molecular mechanisms underlying the potency variability of one LRA: the DNA methylation inhibitor 5-aza-2'-deoxycytidine (5-AzadC).MethodsWe employed epigenetic interrogation methods (electrophoretic mobility shift assays, chromatin immunoprecipitation, Infinium array) in complementary HIV-1 infection models (latently-infected T-cell line models, primary CD4+ T-cell models and ex vivo cultures of PBMCs from HIV+ individuals). Extracellular staining of cell surface receptors and intracellular metabolic activity were measured in drug-treated cells. HIV-1 expression in reactivation studies was explored by combining the measures of capsid p24Gag protein, green fluorescence protein signal, intracellular and extracellular viral RNA and viral DNA.FindingsWe uncovered specific demethylation CpG signatures induced by 5-AzadC in the HIV-1 promoter. By analyzing the binding modalities to these CpG, we revealed the recruitment of the epigenetic integrator Ubiquitin-like with PHD and RING finger domain 1 (UHRF1) to the HIV-1 promoter. We showed that UHRF1 redundantly binds to the HIV-1 promoter with different binding modalities where DNA methylation was either non-essential, essential or enhancing UHRF1 binding. We further demonstrated the role of UHRF1 in the epigenetic repression of the latent viral promoter by a concerted control of DNA and histone methylations.InterpretationA better understanding of the molecular mechanisms of HIV-1 latency allows for the development of innovative antiviral strategies. As a proof-of-concept, we showed that pharmacological inhibition of UHRF1 in ex vivo HIV+ patient cell cultures resulted in potent viral reactivation from latency. Together, we identify UHRF1 as a novel actor in HIV-1 epigenetic silencing and highlight that it constitutes a new molecular target for HIV-1 cure strategies.FundingFunding was provided by the Belgian National Fund for Scientific Research (F.R.S.-FNRS, Belgium), the « Fondation Roi Baudouin », the NEAT (European AIDS Treatment Network) program, the Internationale Brachet Stiftung, ViiV Healthcare, the Télévie, the Walloon Region (« Fonds de Maturation »), « Les Amis des Instituts Pasteur à Bruxelles, asbl », the University of Brussels (Action de Recherche Concertée ULB grant), the Marie Skodowska Curie COFUND action, the European Union's Horizon 2020 research and innovation program under grant agreement No 691119-EU4HIVCURE-H2020-MSCA-RISE-2015, the French Agency for Research on AIDS and Viral Hepatitis (ANRS), the Sidaction and the "Alsace contre le Cancer" Foundation. This work is supported by 1UM1AI164562-01, co-funded by National Heart, Lung and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Institute on Drug Abuse and the National Institute of Allergy and Infectious Diseases.

Published
2022

6. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts

Author

Byonanebye, Dathan M, Polizzotto, Mark N, Maltez, Fernando, Rauch, Andri, Grabmeier-Pfistershammer, Katharina, Wit, Ferdinand, De Wit, Stéphane, Castagna, Antonella, d'Arminio Monforte, Antonella, Mussini, Cristina, Wasmuth, Jan-Christian, Fontas, Eric, Abela, Irene, Sarcletti, Mario, Bansi-Matharu, Loveleen, Jaschinski, Nadine, Peters, Lars, Hosein, Sean R, Vannappagari, Vani, Cohen, Cal, Bissio, Emiliano, Mocroft, Amanda, Law, Matthew, Ryom, Lene, and Petoumenos, Kathy

Published
2024
Full Text
View/download PDF

7. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Author

Martins, Marcelo D, Cahn, Pedro E, Lopardo, Gustavo D, Porteiro, Norma, Bloch, Mark Theo, Baker, David Alfred, Roth, Norman, Moore, Richard J, Finlayson, Robert James, McMahon, James, Rieger, Armin, Zoufaly, Alexander, Schmied, Brigitte, Hartl, Sylvia, Zangerle, Robert, Smaill, Fiona, Walmsley, Sharon L, Conway, Brian, Rachlis, Anita, Smith, Graham H R, Perez Cortes, Carlos, Afani, Alejandro, Campos Barker, Maria Isabel E, Chahin Anania, Carolina Eugenia, Reyes, Marcelo J. Wolff, Gerstoft, Jan, Weis, Nina, Laursen, Alex Lund, Molina, Jean-Michel, Yazdanpanah, Yazdan, Cotte, Laurent, Raffi, Francois, Slama, Laurence, Morlat, Philippe, Girard, Pierre-Marie, Katlama, Christine, Rockstroh, Juergen K, Arasteh, Keikawus, Esser, Stefan, Stoehr, Albrecht, Stellbrink, Hans-Juergen, Stoll, Matthias, Schuermann, Dirk, Faetkenheuer, Gerd, Bogner, Johannes Richard, Lutz, Thomas, Baumgarten, Axel, Jaeger, Hans, Wiese, Carmen, Gori, Andrea, Migliorino, Guglielmo Marco, Coltan, Gabriel, Constandis, Felicia, Erscoiu, Simona M, Prisacariu, Liviu-Jany, Rugina, Sorin, Streinu-Cercel, Adrian, Pokrovsky, Vadim V, Zakharova, Natalia, Shuldyakov, Andrey Anatolyevich, Ryamova, Elena Pavlovna, Kulagin, Valeriy Viktorovich, Tsybakova, Olga Aleksandrovna, Orlova-Morozova, Elena, Nagimova, Firaya, Voronin, Evgeniy, Shimonova, Tatiana Evgenyevna, Kozyrev, Oleg Anatolyevich, Orrell, Catherine, Lombaard, Johannes Jurgens, Botes, Margaretha Elizabeth, de Jager, Marleen, Segorb, Joaquin Portilla, Gatell Artigas, Josep Maria, Mallolas Masferrer, Josep, Guillen, Santiago Moreno, Perez Elias, Maria Jesus, Arribas Lopez, Jose R, Puigmal, Eugenia Negredo, Podzamczer Palter, Daniel, Ortega, Frederico Pulido, Garcia, Jesus Troya, de los Santos Gil, Ignacio, Berenguer, Juan, Nelson, Mark Richard, Williams, Ian G, Johnson, Margaret A, Khoo, Saye, Schembri, Gabriel, Clarke, Amanda, Gompels, Mark, Fox, Julie Meriel, Lwanga, Julianne, Taylor, Steven John, Dockrell, David Harold, Kegg, Stephen, Hagins, Debbie P, Osiyemi, Olayemi O, Prelutsky, David James, Ramgopal, Moti N, Scarsella, Anthony J, Dretler, Robin, DeJesus, Edwin, Bettacchi, Christopher J, Sims III, James, Clay, Patrick G, Bellos, Nicholaos C, Thompson, Melanie A, Montero, Jose, McDonald, Cheryl K, Creticos, Catherine, Shamblaw, David, Terrelonge, Antonio E, Valdes, Martin, Tashima, Karen T, Robbins, William J, Elion, Richard A, Goldstein, Deborah, Slim, Jihad, Lalezari, Jacob Paul, Pushkin, Richard, Lalla-Reddy, Sujata N, Win, Sanda S, Ruane, Peter Jerome, Mills, Anthony Martin, Cade, Jerry L, Campo, Rafael, Dietz, Craig A, Hoffman-Terry, Margaret, Blick, Gary, Rubin, David Scott, Mayer, Cynthia, Rondon, Juan Carlos, Cook, Paul P, Daar, Eric, Kumar, Princy N, Swindells, Susan, Castro, Jose Guillermo, Morales-Ramirez, Javier O, Santiago, Lizette, Santana-Bagur, Jorge L, Vandekerckhove, Linos, Florence, Eric, De Wit, Stephane, Derdelinckx, Inge, Vandercam, Bernard, Belkhir, Leila, De Wet, Joseph, Lebouche, Bertrand, Trottier, Benoit, Longpre, Daniele, Szabo, Jason, LeBlanc, Roger P, Jensen, Werner, Gonzalez, Alvaro Rojas, Beltran, Carlos, Sussmann, Otto Alberto, Velez, Juan Diego, Onate, Jose Millan, Nielsen, Henrik, Degen, Olaf, Stephan, Christoph, Arathoon, Eduardo, Lopez, Rudy Manuel, Rojas Alvarado, Evelyn Michelle, Gonzalez Patzan, Luis Demetrio, Meija, Carlos R, Pinzon, Rodolfo, Parchment, Charles, Sthoeger, Zev, Chowers, Michal, Riesenberg, Klaris, Shahar, Eduardo, Levy, Itzchak, Quintero Perez, Nora Patricia, Andrade-Villanueva, Jaime Federico, Crabtree Ramirez, Brenda Eloisa, Rijnders, Bart, den Hollander, Jan G, Handy, Rupert, Morales, Nilo Bonifacio, Hidalgo, Jose Alfredo, Infante, Rosa Mercedes, Matos Prado, Eduardo Demetrio, Campos, Pablo E, Ticona Chaves, Eduardo Romulo, Pinedo, Yvett, Pacheco, Patricia, Maltez, Fernando Manuel, Cunha, Jose, Neves, Isabel, Serrao, Rosario, Melendez-Rivera, Ivan, Mendoza-Rodriguez, Rafael O, Maldonado-Rivera, Sandra, Ortiz-Lasanta, Grisell, Kizhlo, Svetlana, Freud, Hernando Knobel, Moreno, Jose Sanz, Mendez, Francisco Vera, Mohapi, Lerato, Mitha, Essack Aziz, Mahomed, Akbar Anvar, Fouche, Leon Frederik, Kaplan, Richard, Siddique, Naeem, Hoosen, Farzana, Rassool, Mohammed Siddique, Baraldi, Ezio, Calmy, Alexandra, Cavassini, Matthias, Fehr, Jan, Tsai, Hung-Chin, Lin, Hsi-Hsun, Huang, Chun-Kai, Ko, Wen-Chien, Lin, Yu-Hui, Chen, Su-Jung, Hung, Chien-Ching, Avihingsanon, Anchalee, Kiertiburanakul, Sasisopin, Ratanasuwan, Winai, Supparatpinyo, Khuanchai, Chetchotisakd, Ploenchan, Changpradub, Dhitiwat, Orkin, Chloe, Fox, Ashini, Winston, Alan, Ustianowski, Andrew, Yangco, Bienvenido G, Asmuth, David Michael, Vigil, Karen J, Berger, Daniel S, Bhatti, Laveeza, Campbell, Thomas, Casey, Kathleen K, Liu, Edward, Crofoot, Gordon E, Cunningham, Douglas, Feinberg, Judith, Fichtenbaum, Carl, Balamban Felizarta, Franco Antonio, Jefferson, Thomas T, Johnson, Marc Alexander, Lewis, Stanley T, Luque, Amneris E, Novak, Richard M, Sloan, Louis, Sweet, Donna E, Towner, William J, Zane, Ryan, Riedel, David J, Loftus, Richard Anton, Shon, Alyssa So Young, Mogyoros, Miguel, Tebas, Pablo, Scott, Mia Louise, Parenti, David M, Inciarte Portillo, Alexy, Cahn, Pedro, Lombaard, Johannes, Kumar, Sushma, Campbell, Havilland, Wan, Hong, Teal, Valerie, Jin Xu, Zhi, Asante-Appiah, Ernest, Sklar, Peter, Teppler, Hedy, and Lahoulou, Rima

Published
2024
Full Text
View/download PDF

8. Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study

Author

Lemoine, Maud, Assoumou, Lambert, Girard, Pierre-Marie, Valantin, Marc Antoine, Katlama, Christine, De Wit, Stephane, Campa, Pauline, Rougier, Hayette, Meynard, Jean-Luc, Necsoi, Coca, Huefner, Anja D., Van Luzen, Jan, Schulze zur Wiesch, Julian, Bastard, Jean-Philippe, Fellahi, Soraya, Mauss, Stefan, Stankov, Metodi V., Baumgarten, Axel, Post, Gerrit, Serfaty, Lawrence, Ratziu, Vlad, Menu, Yves, Schlue, Jerome, Bedossa, Pierre, Capeau, Jacqueline, Costagliola, Dominique, Behrens, Georg, and Ingiliz, Patrick

Published
2023
Full Text
View/download PDF

9. Chronic liver enzyme elevation and use of contemporary ARVs among persons living with HIV

Author

Roen, Ashley O, primary, Peters, Lars, additional, Wandeler, Gilles, additional, van der Valk, Marc, additional, Zangerle, Robert, additional, Günthard, Huldrych F, additional, Wit, Ferdinand, additional, Mussini, Cristina, additional, De Wit, Stéphane, additional, d’Arminio Monforte, Antonella, additional, Vehreschild, Jörg Janne, additional, Castagna, Antonella, additional, Jaschinski, Nadine, additional, Vannappagari, Vani, additional, Chen, Linda, additional, Tallada, Joan, additional, C’mar, John, additional, Mocroft, Amanda, additional, and Ryom, Lene, additional

Published
2024
Full Text
View/download PDF

10. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium

Author

Neesgaard, Bastian, Greenberg, Lauren, Miró, Jose M, Grabmeier-Pfistershammer, Katharina, Wandeler, Gilles, Smith, Colette, De Wit, Stéphane, Wit, Ferdinand, Pelchen-Matthews, Annegret, Mussini, Cristina, Castagna, Antonella, Pradier, Christian, d'Arminio Monforte, Antonella, Vehreschild, Jörg J, Sönnerborg, Anders, Anne, Alain V, Carr, Andrew, Bansi-Matharu, Loveleen, Lundgren, Jens D, Garges, Harmony, Rogatto, Felipe, Zangerle, Robert, Günthard, Huldrych F, Rasmussen, Line D, Necsoi, Coca, van der Valk, Marc, Menozzi, Marianna, Muccini, Camilla, Peters, Lars, Mocroft, Amanda, and Ryom, Lene

Published
2022
Full Text
View/download PDF

11. A public health value-based healthcare paradigm for HIV

Author

Vermeersch, Sebastian, Demeester, Rémy P., Ausselet, Nathalie, Callens, Steven, De Munter, Paul, Florence, Eric, Goffard, Jean-Christophe, Henrard, Sophie, Lacor, Patrick, Messiaen, Peter, Libois, Agnès, Seyler, Lucie, Uurlings, Françoise, Vandecasteele, Stefaan J., Van Wijngaerden, Eric, Yombi, Jean-Cyr, Annemans, Lieven, and De Wit, Stéphane

Published
2022
Full Text
View/download PDF

12. A Characterization of Women Living with HIV in Belgium.

Author

Nasreddine, Rakan, Yombi, Jean Cyr, Darcis, Gilles, Van Frankenhuijsen, Maartje, Van Petersen, Lida, Abels, Chloé, Dos Santos Mendes, Sofia, Delforge, Marc, De Wit, Stéphane, and Wang, Taiyao

Abstract

Objectives. The primary objective of this study was to characterize women living with HIV (WLWH) in Belgium. The secondary objective was an exploratory analysis comparing women and men living with HIV (MLWH). Methods. This was a cross‐sectional, observational, multicenter study. Inclusion criteria for the primary objective were all adult treatment‐naïve and experienced WLWH actively being treated at one of the participating centers. For the secondary objective, inclusion criteria were all adult naïve and experienced women and MLWH, actively being treated at a single participating center. Data were collected between December 2022 and March 2023. A multivariable analysis was performed on all women included to evaluate for associations with having hypertension (HTN) or being virologically nonsuppressed (HIV‐1 VL ≥200 copies/mL). In the exploratory analysis of women and MLWH, a multivariable analysis was carried out to evaluate whether female gender was associated with having HTN or being virologically nonsuppressed. Results. Overall, 2797 WLWH were included. The majority were Black (73.5%) and 48.5% were aged ≥50 years. The most common comorbidity was HTN (17.3%) and most individuals were virologically suppressed (HIV‐1 VL <50 copies/mL; 85.6%). Black race was associated with having HTN (p < 0.0001). Prior AIDS‐defining illness (p = 0.02) and a CD4+ T‐cell count <500 cells/µL (p < 0.0001) were associated with being nonsuppressed. A total of 1094 WLWH and 1878 MLWH were included in the exploratory analysis. HTN was higher among WLWH (20.2% vs. 12% MLWH). Female gender was not found to be associated with having HTN (p = 0.86) or being nonsuppressed (p = 0.14). Conclusion. In this analysis of WLWH in Belgium, the results depict an ageing population that is predominantly Black. The most common comorbidity observed was HTN. Women had a low rate of virologic nonsuppression, and female gender was not associated with being nonsuppressed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide–Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196

Author

De Wit, Stéphane, primary, Bonnet, Fabrice, additional, Osiyemi, Olayemi, additional, Bisshop, Fiona, additional, Olalla, Julian, additional, Routy, Jean-Pierre, additional, Wyen, Christoph, additional, Moodley, Riya, additional, Pappa, Keith, additional, Wang, Ruolan, additional, Oyee, James, additional, Saggu, Parminder, additional, Letang, Emilio, additional, Wynne, Brian, additional, Jones, Bryn, additional, Smith, Kimberly Y., additional, and Ait-Khaled, Mounir, additional

Published
2024
Full Text
View/download PDF

14. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium

Author

Bansi-Matharu, Loveleen, Phillips, Andrew, Oprea, Cristiana, Grabmeier-Pfistershammer, Katharina, Günthard, Huldrych F, De Wit, Stephane, Guaraldi, Giovanni, Vehreschild, Jorg J, Wit, Ferdinand, Law, Matthew, Wasmuth, Jan-Christian, Chkhartishvili, Nikoloz, d'Arminio Monforte, Antonella, Fontas, Eric, Vesterbacka, Jan, Miro, Jose M, Castagna, Antonella, Stephan, Christoph, Llibre, Josep M, Neesgaard, Bastian, Greenberg, Lauren, Smith, Colette, Kirk, Ole, Duvivier, Claudine, Dragovic, Gordana, Lundgren, Jens, Dedes, Nikos, Knudsen, Andreas, Gallant, Joel, Vannappagari, Vani, Peters, Lars, Elbirt, Daniel, Sarcletti, Mario, Braun, Dominique L, Necsoi, Coca, Mussini, Cristina, Muccini, Camilla, Bolokadze, Natalie, Hoy, Jennifer, Mocroft, Amanda, and Ryom, Lene

Published
2021
Full Text
View/download PDF

16. Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study

Author

Judd, Ali, Zangerle, Robert, Touloumi, Giota, Warszawski, Josiane, Meyer, Laurence, Dabis, François, Krause, Murielle Mary, Ghosn, Jade, Leport, Catherine, Wittkop, Linda, Reiss, Peter, Wit, Ferdinand, Prins, Maria, Bucher, Heiner, Gibb, Diana, Fätkenheuer, Gerd, Julia, Del Amo, Obel, Niels, Thorne, Claire, Mocroft, Amanda, Kirk, Ole, Stephan, Christoph, Pérez-Hoyos, Santiago, Hamouda, Osamah, Bartmeyer, Barbara, Chkhartishvili, Nikoloz, Noguera-Julian, Antoni, Antinori, Andrea, Monforte, Antonella d’Arminio, Brockmeyer, Norbert, Prieto, Luis, Conejo, Pablo Rojo, Soriano-Arandes, Antoni, Battegay, Manuel, Kouyos, Roger, Mussini, Cristina, Tookey, Pat, Casabona, Jordi, Miró, Jose M, Castagna, Antonella, Konopnick, Deborah, Goetghebuer, Tessa, Sönnerborg, Anders, Quiros-Roldan, Eugenia, Sabin, Caroline, Teira, Ramon, Garrido, Myriam, Haerry, David, de Wit, Stéphane, Costagliola, Dominique, d’Arminio-Monforte, Antonella, del Amo, Julia, Raben, Dorthe, Chêne, Geneviève, Rojo, Conejo Pablo, Barger, Diana, Schwimmer, Christine, Termote, Monique, Campbell, Maria, Frederiksen, Casper M, Friis-Møller, Nina, Kjaer, Jesper, Brandt, Rikke Salbøl, Berenguer, Juan, Bohlius, Julia, Bouteloup, Vincent, Cozzi-Lepri, Alessandro, Davies, Mary-Anne, Dorrucci, Maria, Dunn, David, Egger, Matthias, Furrer, Hansjakob, Grabar, Sophie, Guiguet, Marguerite, Lambotte, Olivier, Leroy, Valériane, Lodi, Sara, Matheron, Sophie, Miro, Jose M, Monge, Susana, Nakagawa, Fumiyo, Paredes, Roger, Phillips, Andrew, Puoti, Massimo, Rohner, Eliane, and Schomaker, Michael

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Sexually Transmitted Infections, Rare Diseases, Emerging Infectious Diseases, Infectious Diseases, HIV/AIDS, Infection, Adolescent, Adult, Anti-Retroviral Agents, CD4 Lymphocyte Count, Cohort Studies, Female, HIV Infections, HIV-1, Humans, Male, Middle Aged, Risk Factors, Sarcoma, Kaposi, Viral Load, Young Adult, AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord, HIV, Kaposi sarcoma, antiretroviral therapy, cohort study, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundWe compared Kaposi sarcoma (KS) risk in adults who started antiretroviral therapy (ART) across the Asia-Pacific, South Africa, Europe, Latin, and North America.MethodsWe included cohort data of human immunodeficiency virus (HIV)-positive adults who started ART after 1995 within the framework of 2 large collaborations of observational HIV cohorts. We present incidence rates and adjusted hazard ratios (aHRs).ResultsWe included 208140 patients from 57 countries. Over a period of 1066572 person-years, 2046 KS cases were diagnosed. KS incidence rates per 100000 person-years were 52 in the Asia-Pacific and ranged between 180 and 280 in the other regions. KS risk was 5 times higher in South African women (aHR, 4.56; 95% confidence intervals [CI], 2.73-7.62) than in their European counterparts, and 2 times higher in South African men (2.21; 1.34-3.63). In Europe, Latin, and North America KS risk was 6 times higher in men who have sex with men (aHR, 5.95; 95% CI, 5.09-6.96) than in women. Comparing patients with current CD4 cell counts ≥700 cells/µL with those whose counts were

Published
2017

17. Chronic Liver Enzyme Elevation and Use of Contemporary ARVs Among People With HIV

Author

Roen, Ashley, Peters, Lars, Wandeler, Gilles, Van Der Valk, Marc, Zangerle, Robert, Günthard, Hüldrych Fritz, Wit, Ferdinand, Mussini, Cristina, De Wit, Stéphane, D’Arminio Monforte, Antonella, Vehreschild, Jörg Janne, Castagna, Antonella, Jaschinski, Nadine, Vannappagari, Vani, Chen, Linda, Tallada, Joan, C’mar, John, Mocroft, Amanda, Ryom, Lene, Roen, Ashley, Peters, Lars, Wandeler, Gilles, Van Der Valk, Marc, Zangerle, Robert, Günthard, Hüldrych Fritz, Wit, Ferdinand, Mussini, Cristina, De Wit, Stéphane, D’Arminio Monforte, Antonella, Vehreschild, Jörg Janne, Castagna, Antonella, Jaschinski, Nadine, Vannappagari, Vani, Chen, Linda, Tallada, Joan, C’mar, John, Mocroft, Amanda, and Ryom, Lene

Abstract

Background. While use of some older antiretroviral drugs (ARVs) is associated with chronic liver enzyme elevation (cLEE), the impact of newer ARVs remains unknown. Methods. People with HIV enrolled in the RESPOND cohort who started an ARV after January 1, 2012 were included (baseline). The primary outcome was first cLEE individuals were censored at first of cLEE, last visit, death, or December 31, 2021. Incidence rates (IRs; events/1000 person-years) were calculated for each ARV overall and by ARV exposure (6–12 months, 1–2 years, and 2+ years). Poisson regression was used to estimate the incidence rate ratio (IRR) of cLEE and its association with individual ARVs and ARV class. Results. Of 17 106 individuals included contributing 87 924 person-years of follow-up, 1932 (11.3%) experienced cLEE (incidence rate [IR], 22.0; 95% CI, 21.0–23.0). There was no evidence of a cumulative ARV effect on cLEE incidence, (6–12 months: IR, 45.8; 95% CI, 41.4–50.19; 1–2 years: IR, 34.3; 95% CI, 31.5–37.4; and 2+ years: IR, 18.5; 95% CI, 17.4–19.7). Any use (vs no prior use) of non-nucleoside reverse transcriptase inhibitors (NNRTIs) as a class and tenofovir disoproxil fumarate (TDF) was independently associated with an increased IRR of cLEE, and any use of darunavir (DRV) was associated with a decreased risk of cLEE. Conclusions. cLEE is common and more frequent during the first year after initiating new ARVs. With a >5-year median follow-up, we found no short-term liver safety concerns with the use of INSTIs. Use of NNRTIs and TDF was associated with an increased cLEE risk, while DRV was associated with lower risk., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2024

18. Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings.

Author

Jonsson-Oldenbüttel, Celia, Ghosn, Jade, van der Valk, Marc, Florence, Eric, Vera, Francisco, De Wit, Stéphane, Rami, Agathe, Bonnet, Fabrice, Hocqueloux, Laurent, Hove, Kai, Ait-Khaled, Mounir, DeMoor, Rebecca, Bontempo, Gilda, Latham, Christine L., Gutner, Cassidy A., Iyer, Supriya, Gill, Martin, Czarnogorski, Maggie, D'Amico, Ronald, and van Wyk, Jean

Published
2024
Full Text
View/download PDF

27. Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting

Author

Greenberg, Lauren, Ryom, Lene, Wandeler, Gilles, Grabmeier-Pfistershammer, Katharina, Öllinger, Angela, Neesgaard, Bastian, Stephan, Christoph, Calmy, Alexandra, Rauch, Andri, Castagna, Antonella, Spagnuolo, Vincenzo, Johnson, Margaret, Stingone, Christof, Mussini, Cristina, De Wit, Stéphane, Necsoi, Coca, Campins, Antoni A., Pradier, Christian, Stecher, Melanie, Wasmuth, Jan-Christian, Monforte, Antonella dʼArminio, Law, Matthew, Puhr, Rainer, Chkhartishvilli, Nikoloz, Tsertsvadze, Tengiz, Garges, Harmony, Thorpe, David, Lundgren, Jens D., Peters, Lars, Bansi-Matharu, Loveleen, and Mocroft, Amanda

Published
2020
Full Text
View/download PDF

28. Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1

Author

Stirrup, Oliver, Sterne, Jonathan, Dunn, David T., Grabmeier-Pfistershammer, Katharina, Papastamopoulos, Vasileios, Vandenhende, Marie-Anne, Wit, Ferdinand, Porter, Kholoud, Gunsenheimer-Bartmeyer, Barbara, Jarrin, Inma, Garcia, Federico, Fätkenheuer, Gerd, Obel, Niels, Schultze, Anna, Antinori, Andrea, Ceccherini-Silberstein, Francesca, Mussini, Cristina, Chêne, Geneviève, Neesgaard, Bastian, Castagna, Antonella, Kouyos, Roger, De Wit, Stéphane, Sönnerborg, Anders, Sabin, Caroline, Merino, Dolores, Barger, Diana, and Phillips, Andrew

Published
2019
Full Text
View/download PDF

31. Helicobacter pylori and Human Immunodeficiency Virus Co-Infection: Potential Implications for Future Gastric Cancer Risk

Author

Nkuize, Marcel, De Wit, Stéphane, Demetter, Pieter, Eisendrath, Pierre, Vanderpas, Jean-Baptiste, Nkuize, Marcel, De Wit, Stéphane, Demetter, Pieter, Eisendrath, Pierre, and Vanderpas, Jean-Baptiste

Abstract

Objective: Helicobacter pylori and human immunodeficiency virus (HIV) are both pandemic infections with variable geographic prevalence rates. H. pylori–HIV co-infection at the regional and sub-regional levels with a perspective on gastric cancer incidence is discussed. Design: Based on PRISMA guidelines, national data for H. pylori, HIV, and H. pylori–HIV co-infection were collected for the general population through December 2019. Joint temporal and geographical data for H. pylori and HIV infections in 48 countries were available and used to generate H. pylori–HIV co-infection estimates by cross-sectional analysis. These data were compared with gastric carcinoma statistics for the same countries. Results: The estimated global prevalence rate of H. pylori–HIV co-infection was 1.7 per 1000 people, representing 12.6 million people. Prevalence according to region was, in decreasing order, sub-Saharan Africa 21.9‰, Eastern Europe/Central Asia 4.3‰, Latin America/Caribbean 2.0 ‰, North America/Western/Southern/Northern Europe 1.1‰, Asia/Pacific 0.8‰, and North Africa/Middle East 0.1 ‰. The incidence and mortality rates for gastric carcinoma were higher in East/Pacific Asia, Southern/Andean Latin America, and Eastern Europe regions, and the incidence appeared to be 1.8-fold greater in H. pylori–HIV-infected people in East Asia. Conclusions: The population at risk of H. pylori–HIV co-infection is estimated to be 12.6 million people (2015 reference year). The heterogeneity of H. pylori–HIV co-infection across regions and sub-regions does not show a clear association with gastric carcinoma. Other methodological approaches with analytical studies (cohort, case–control) are required to measure the potential effect of H. pylori infection and its treatment on the incidence of gastric carcinoma in the large HIV–H. pylori-positive cohort., SCOPUS: ar.j, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2023

32. Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV

Author

Greenberg, Lauren, Ryom, Lene, Bakowska, Elzbieta, Wit, Ferdinand, Bucher, Heiner C; https://orcid.org/0000-0002-0131-7873, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Phillips, Andrew; https://orcid.org/0000-0003-2384-4807, Sabin, Caroline; https://orcid.org/0000-0001-5173-2760, d'Arminio Monforte, Antonella; https://orcid.org/0000-0003-0073-1789, Zangerle, Robert; https://orcid.org/0000-0002-5375-7299, Smith, Colette, De Wit, Stéphane; https://orcid.org/0000-0002-8079-6170, Bonnet, Fabrice, Pradier, Christian, Mussini, Cristina, Muccini, Camilla; https://orcid.org/0000-0002-0900-5639, Vehreschild, Jörg J, Hoy, Jennifer; https://orcid.org/0000-0002-6948-7086, Svedhem, Veronica, Miró, Jose M; https://orcid.org/0000-0001-8057-7755, Wasmuth, Jan-Christian, Reiss, Peter; https://orcid.org/0000-0001-7896-6428, Llibre, Josep M; https://orcid.org/0000-0002-7158-6753, Chkhartishvili, Nikoloz, Stephan, Christoph; https://orcid.org/0000-0003-3777-9006, Hatleberg, Camilla I; https://orcid.org/0000-0002-4396-6281, Neesgaard, Bastian; https://orcid.org/0000-0003-0215-0144, Peters, Lars, Jaschinski, Nadine; https://orcid.org/0000-0003-4847-2966, Dedes, Nikos, et al, Greenberg, Lauren, Ryom, Lene, Bakowska, Elzbieta, Wit, Ferdinand, Bucher, Heiner C; https://orcid.org/0000-0002-0131-7873, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Phillips, Andrew; https://orcid.org/0000-0003-2384-4807, Sabin, Caroline; https://orcid.org/0000-0001-5173-2760, d'Arminio Monforte, Antonella; https://orcid.org/0000-0003-0073-1789, Zangerle, Robert; https://orcid.org/0000-0002-5375-7299, Smith, Colette, De Wit, Stéphane; https://orcid.org/0000-0002-8079-6170, Bonnet, Fabrice, Pradier, Christian, Mussini, Cristina, Muccini, Camilla; https://orcid.org/0000-0002-0900-5639, Vehreschild, Jörg J, Hoy, Jennifer; https://orcid.org/0000-0002-6948-7086, Svedhem, Veronica, Miró, Jose M; https://orcid.org/0000-0001-8057-7755, Wasmuth, Jan-Christian, Reiss, Peter; https://orcid.org/0000-0001-7896-6428, Llibre, Josep M; https://orcid.org/0000-0002-7158-6753, Chkhartishvili, Nikoloz, Stephan, Christoph; https://orcid.org/0000-0003-3777-9006, Hatleberg, Camilla I; https://orcid.org/0000-0002-4396-6281, Neesgaard, Bastian; https://orcid.org/0000-0003-0215-0144, Peters, Lars, Jaschinski, Nadine; https://orcid.org/0000-0003-4847-2966, Dedes, Nikos, and et al

Abstract

Despite cancer being a leading comorbidity amongst individuals with HIV, there are limited data assessing cancer trends across different antiretroviral therapy (ART)-eras. We calculated age-standardised cancer incidence rates (IRs) from 2006-2021 in two international cohort collaborations (D:A:D and RESPOND). Poisson regression was used to assess temporal trends, adjusted for potential confounders. Amongst 64,937 individuals (31% ART-naïve at baseline) and 490,376 total person-years of follow-up (PYFU), there were 3763 incident cancers (IR 7.7/1000 PYFU [95% CI 7.4, 7.9]): 950 AIDS-defining cancers (ADCs), 2813 non-ADCs, 1677 infection-related cancers, 1372 smoking-related cancers, and 719 BMI-related cancers (groups were not mutually exclusive). Age-standardised IRs for overall cancer remained fairly constant over time (8.22/1000 PYFU [7.52, 8.97] in 2006-2007, 7.54 [6.59, 8.59] in 2020-2021). The incidence of ADCs (3.23 [2.79, 3.72], 0.99 [0.67, 1.42]) and infection-related cancers (4.83 [4.2, 5.41], 2.43 [1.90, 3.05]) decreased over time, whilst the incidence of non-ADCs (4.99 [4.44, 5.58], 6.55 [5.67, 7.53]), smoking-related cancers (2.38 [2.01, 2.79], 3.25 [2.63-3.96]), and BMI-related cancers (1.07 [0.83, 1.37], 1.88 [1.42, 2.44]) increased. Trends were similar after adjusting for demographics, comorbidities, HIV-related factors, and ART use. These results highlight the need for better prevention strategies to reduce the incidence of NADCs, smoking-, and BMI-related cancers.

Published
2023

33. Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV

Author

Jaschinski, Nadine, Greenberg, Lauren, Neesgaard, Bastian, Miró, Jose M., Grabmeier-Pfistershammer, Katharina, Wandeler, Gilles, Smith, Colette, De Wit, Stéphane, Wit, Ferdinand, Pelchen-Matthews, Annegret, Mussini, Cristina, Castagna, Antonella, Pradier, Christian, D'Arminio Monforte, Antonella, Vehreschild, Jörg, Sönnerborg, Anders, Anne, Alain V., Carr, Andrew, Bansi-Matharu, Loveleen, Lundgren, Jens, Garges, Harmony, Rogatto, Felipe, Zangerle, Robert, Günthard, Huldrych F., Rasmussen, Line D., Nescoi, Coca, Van Der Valk, Marc, Menozzi, Marianna, Muccini, Camilla, Mocroft, Amanda, Peters, Lars, Ryom, Lene, Jaschinski, Nadine, Greenberg, Lauren, Neesgaard, Bastian, Miró, Jose M., Grabmeier-Pfistershammer, Katharina, Wandeler, Gilles, Smith, Colette, De Wit, Stéphane, Wit, Ferdinand, Pelchen-Matthews, Annegret, Mussini, Cristina, Castagna, Antonella, Pradier, Christian, D'Arminio Monforte, Antonella, Vehreschild, Jörg, Sönnerborg, Anders, Anne, Alain V., Carr, Andrew, Bansi-Matharu, Loveleen, Lundgren, Jens, Garges, Harmony, Rogatto, Felipe, Zangerle, Robert, Günthard, Huldrych F., Rasmussen, Line D., Nescoi, Coca, Van Der Valk, Marc, Menozzi, Marianna, Muccini, Camilla, Mocroft, Amanda, Peters, Lars, and Ryom, Lene

Abstract

Objective:Assessing whether the previously reported association between abacavir (ABC) and cardiovascular disease (CVD) remained amongst contemporarily treated people with HIV.Design:Multinational cohort collaboration.Methods:RESPOND participants were followed from the latest of 1 January 2012 or cohort enrolment until the first of a CVD event (myocardial infarction, stroke, invasive cardiovascular procedure), last follow-up or 31 December 2019. Logistic regression examined the odds of starting ABC by 5-year CVD or chronic kidney disease (CKD) D:A:D risk score. We assessed associations between recent ABC use (use within the past 6 months) and risk of CVD with negative binomial regression models, adjusted for potential confounders.Results:Of 29 340 individuals, 34% recently used ABC. Compared with those at low estimated CVD and CKD risks, the odds of starting ABC were significantly higher among individuals at high CKD risk [odds ratio 1.12 (95% confidence interval = 1.04-1.21)] and significantly lower for individuals at moderate, high or very high CVD risk [0.80 (0.72-0.88), 0.75 (0.64-0.87), 0.71 (0.56-0.90), respectively]. During 6.2 years of median follow-up (interquartile range; 3.87-7.52), there were 748 CVD events (incidence rate 4.7 of 1000 persons-years of follow up (4.3-5.0)]. The adjusted CVD incidence rate ratio was higher for individuals with recent ABC use [1.40 (1.20-1.64)] compared with individuals without, consistent across sensitivity analyses. The association did not differ according to estimated CVD (interaction P = 0.56) or CKD (P = 0.98) risk strata.Conclusion:Within RESPOND's contemporarily treated population, a significant association between CVD incidence and recent ABC use was confirmed and not explained by preferential ABC use in individuals at increased CVD or CKD risk.

Published
2023

37. HIV-Related Immune Activation Compromises Polyfunctional IgG and Memory B-Cell Responses to Tdap Immunization during Pregnancy

Author

Taton, Martin, primary, Willems, Fabienne, additional, Widomski, Cyprien, additional, Georges, Daphnéee, additional, Martin, Charlotte, additional, Jiang, Yiwei, additional, Renard, Katty, additional, Konopnicki, Deborah, additional, Cogan, Alexandra, additional, Necsoi, Coca, additional, De Wit, Stéphane, additional, Ackerman, Margaret E., additional, Marchant, Arnaud, additional, and Dauby, Nicolas, additional

Published
2023
Full Text
View/download PDF

38. Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

Author

Bernardino, Jose I, Mocroft, Amanda, Mallon, Patrick W, Wallet, Cedrick, Gerstoft, Jan, Russell, Charlotte, Reiss, Peter, Katlama, Christine, De Wit, Stephane, Richert, Laura, Babiker, Abdel, Buño, Antonio, Castagna, Antonella, Girard, Pierre-Marie, Chene, Genevieve, Raffi, Francois, and Arribas, Jose R

Published
2015
Full Text
View/download PDF

39. Plasma HIV-1 RNA and CD4+ T-cell counts are determinants of virological non-suppression outcomes with initial integrase inhibitor-based regimens: A prospective RESPOND cohort study

Author

Álvarez, Hortensia, Mocroft, Amanda, Ryom, Lene, Neesgaard, Bastian, Edwards, Simon, Svedhem, Vero-Nica, Günthard, Huldrych F, Zangerle, Robert, Smith, Colette, Castagna, Antonella, D Arminio Monforte, Antonella, Wit, Ferdinand, Stecher, Melanie, Lehman, Clara, Mussini, Cristina, Fontas, Eric, González, Eva, Wasmuth, Jan-Christian, Sönnerborg, Anders, De Wit, Stéphane, Chkhartishvili, Nikoloz, Stephan, Christoph, Petoumenos, Kathy, Jaschinski, Nadine, Vannappagari, Vani, Gallant, Joel, Young, Lital, Volny Anne, Alain, Greenberg, Lauren, Martín-Iguacel, Raquel, Poveda, Eva, and Llibre, Josep M

Subjects
integrase inhibitors, residual viremia, virological failure, blip, low-level viremia, dolutegravir
Published
2023

40. Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on‐going viral transcription

Author

Pannus, Pieter, Rutsaert, Sofie, De Wit, Stéphane, Allard, Sabine D., Vanham, Guido, Cole, Basiel, Nescoi, Coca, Aerts, Joeri, De Spiegelaere, Ward, Tsoumanis, Achilleas, Couttenye, Marie?Madeleine, Herssens, Natacha, De Scheerder, Marie?Angélique, Vandekerckhove, Linos, and Florence, Eric

Subjects
Antiviral agents -- Dosage and administration, Viremia -- Measurement, HIV infection -- Development and progression -- Drug therapy, Health
Abstract

: Introduction: Viral remission after analytical treatment interruption (ATI), termed post‐treatment control, has been described in a small proportion of HIV‐positive patients. This phenomenon has been separately associated to both low levels of HIV‐1 proviral DNA as well as cell‐associated RNA. We investigated whether the combination of both parameters could help predict delayed viral rebound after treatment interruption (TI). Methods: We conducted an open single‐arm ATI study in four Belgian HIV reference centres from January 2016 to July 2018. Eligible participants were adults who had fewer than 50 HIV‐1 RNA copies/mL for more than two years, more than 500 CD4 cells/µL for more than three months, and were in general good health. Consenting participants who had fewer than 66 copies total HIV‐1 DNA (t‐DNA) and fewer than 10 copies cell‐associated HIV‐1 unspliced RNA (US‐RNA) per million peripheral blood mononuclear cells (PBMCs), interrupted therapy and were monitored closely. Antiretroviral therapy (ART) was resumed after two consecutive viral loads exceeding 1000 copies or one exceeding 10,000 copies/mL. The primary outcome was the proportion of participants with fewer than 50 HIV‐1 RNA copies/mL 48 weeks after TI. Secondary outcomes were time to viral rebound, the frequency of serious adverse events (AEs) and evolution of t‐DNA and US‐RNA after TI. Results: All 16 consenting participants who interrupted therapy experienced rapid viral rebound two to eight weeks after TI. No serious AEs were observed. Levels of t‐DNA and US‐RNA increased after TI but returned to pre‐ATI levels after treatment restart. None of the studied demographic, clinical and biological parameters were predictive of time of viral rebound. Conclusions: The combination of low levels of t‐DNA and US‐RNA in PBMCs, corresponding respectively to a small and transcriptionally silent viral reservoir, is not predictive of viral remission after TI in patients on ART., Introduction Although antiretroviral therapy (ART) effectively blocks HIV replication, HIV persists in a reservoir of latently infected CD4+ T cells. This causes most patients to experience viral rebound within weeks [...]

Published
2020
Full Text
View/download PDF

45. HIV incidence in the Estonian population in 2013 determined using the HIV‐1 limiting antigen avidity assay

Author

Soodla, P, Simmons, R, Huik, K, Pauskar, M, Jõgeda, E‐L, Rajasaar, H, Kallaste, E, Maimets, M, Avi, R, Murphy, G, Porter, K, Lutsar, I, Del Amo, Julia, Meyer, Laurence, Bucher, Heiner C., Chêne, Geneviève, Hamouda, Osamah, Pillay, Deenan, Prins, Maria, Rosinska, Magda, Sabin, Caroline, Touloumi, Giota, Olson, Ashley, Cartier, Andrea, Fradette, Lorraine, Walker, Sarah, Babiker, Abdel, De Luca, Andrea, Fisher, Martin, Muga, Roberto, Kelleher, Tony, Cooper, David, Grey, Pat, Finlayson, Robert, Bloch, Mark, Ramacciotti, Tim, Gelgor, Linda, Smith, Don, Zangerle, Robert, Gill, John, Dabis, Francois, Thiebaut, Rodolphe, Costagliola, Dominique, Guiguet, Marguerite, Vanhems, Philippe, Chaix, Marie‐Laure, Ghosn, Jade, Boufassa, Faroudy, Meixenberger, Karolin, Bannert, Norbert, Bartmeyer, Barbara, Antoniadou, Anastasia, Chrysos, Georgios, Daikos, Georgios L., Pantazis, Nikos, Katsarou, Olga, Rezza, Giovanni, Dorrucci, Maria, Monforte, Antonella dʼArminio, Geskus, Ronald, van der Helm, Jannie, Schuitemaker, Hanneke, Sannes, Mette, Brubakk, Oddbjorn, Kran, Anne‐Marte Bakken, Rosinska, Magdalena, Tor, Jordi, de Olalla, Patricia Garcia, Cayla, Joan, Moreno, Santiago, Monge, Susana, del Romero, Jorge, Pérez‐Hoyos, Santiago, Sönnerborg, Anders, Günthard, Huldrych, Scherrer, Alexandra, Malyuta, Ruslan, Johnson, Anne, Phillips, Andrew, Morrison, Charles, Price, Matt A., Giaquinto, Carlo, Grarup, Jesper, Kirk, Ole, Bailey, Heather, Volny Anne, Alain, Panteleev, Alex, Thorne, Claire, Aboulker, Jean‐Pierre, Albert, Jan, Asandi, Silvia, De Wit, Stéphane, Reiss, Peter, Gatell, José, Karpov, Igor, Ledergerber, Bruno, Møller, Claus, Rakhmanova, Aza, Rockstroh, Jürgen, Sandhu, Manjinder, Dedes, Nikos, Pizzuti, David, Faggion, Silvia, Raben, Dorthe, Schwimmer, Christine, and Scott, Martin

Published
2018
Full Text
View/download PDF

46. Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery

Author

Antiretroviral Therapy Cohort Collaboration (ART-CC), Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Engsig, Frederik N., Zangerle, Robert, Katsarou, Olga, Dabis, Francois, Reiss, Peter, Gill, John, Porter, Kholoud, Sabin, Caroline, Riordan, Andrew, Fätkenheuer, Gerd, Gutiérrez, Félix, Raffi, Francois, Kirk, Ole, Mary-Krause, Murielle, Stephan, Christoph, de Olalla, Patricia Garcia, Guest, Jodie, Samji, Hasina, Castagna, Antonella, d'Arminio Monforte, Antonella, Skaletz-Rorowski, Adriane, Ramos, Jose, Lapadula, Giuseppe, Mussini, Cristina, Force, Lluís, Meyer, Laurence, Lampe, Fiona, Boufassa, Foroudy, Bucher, Heiner C., De Wit, Stéphane, Burkholder, Greer A., Teira, Ramon, Justice, Amy C., Sterling, Tim R., Crane, Heidi M., Gerstoft, Jan, Grarup, Jesper, May, Margaret, Chêne, Geneviève, Ingle, Suzanne M., Sterne, Jonathan, and Obel, Niels

Published
2014
Full Text
View/download PDF

48. List of Contributors

Author

Abrahamian, Fredrick M., primary, Aldape, Michael J., additional, Aldasoro, Edelweiss, additional, Allen, Upton D., additional, Al-Sum, Hythem, additional, Anadkat, Milan J., additional, Anders, Katherine, additional, Angelakis, Emmanouil, additional, Angus, Brian John, additional, Antoniadou, Anastasia, additional, Arena, Fabio, additional, Arends, Joop E., additional, Arribas, Jose R., additional, Artenstein, Andrew W., additional, Atherton, John C., additional, Aucott, John N., additional, Aw, Tar-Ching, additional, Babcock, Hilary M., additional, Bailey, Robin, additional, Bailey, Thomas C., additional, Banks, Adam Z., additional, Barillo, David J., additional, Barrette, Ernie-Paul, additional, Bauer, Martijn P., additional, Bayston, Roger, additional, Beard, C. Ben, additional, Beardsley, Justin, additional, Beeching, Nick J., additional, Bégué, Rodolfo E., additional, Beldi, Guido, additional, Benson, Constance A., additional, Berbari, Elie F., additional, Berenger, Jean-Michel, additional, Berger, Christoph, additional, Bernardino, Jose I., additional, Bille, Jacques, additional, Billioux, Alexander C., additional, Bitnun, Ari, additional, Blair, Iain, additional, Blanche, Stéphane, additional, Bleck, Thomas P., additional, Bleeker-Rovers, Chantal P., additional, Bleijenberg, Gijs, additional, Bloch, Karen C., additional, Blum, Johannes, additional, Blumberg, Emily A., additional, Bonomo, Robert A., additional, Bonten, Marc J.M., additional, Bourayou, Rafik, additional, Bouza, Emilio, additional, Brandt, K. Ashley, additional, Bretelle, Florence, additional, Brisse, Sylvain, additional, Britton, Warwick J., additional, Brook, Itzhak, additional, Brouwer, Matthijs C., additional, Browne, Sarah K., additional, Bryant, Amy E., additional, Bühler, Silja, additional, Bulger, Eileen M., additional, Buller, R. Mark L., additional, Burke, Leah A., additional, Burri, Christian, additional, Butler, Marcus W., additional, Calandra, Thierry, additional, Calfee, David P., additional, Calvo-Cano, Antonia, additional, Cameron, D. William, additional, Carcillo, Joseph A., additional, Carson, Gail, additional, Chambers, Stephen T., additional, Charrel, Remi N., additional, Nguyen, Vinh Chau Van, additional, Chevaliez, Stéphane, additional, Chiller, Tom M., additional, Christaki, Eirini, additional, Chung, Kevin K., additional, Clifford, David B., additional, Clumeck, Nathan, additional, Cohen, Jonathan, additional, Collinge, John, additional, Conlon, Christopher P., additional, Conrad, Curdin, additional, Cooke, Fiona J., additional, Cope, Jennifer Rittenhouse, additional, Corey, G. Ralph, additional, Cross, John H., additional, Cunha, Burke A., additional, Cunha, Cheston B., additional, D'Journo, Benoit, additional, Daikos, George L., additional, Daniels, Johannes M.A., additional, Davidson, Robert N., additional, Day, Nicholas P.J., additional, De Cock, Kevin M., additional, de Silva, Thushan I., additional, de Vries, Henry J.C., additional, de Wit, Stéphane, additional, Delaloye, Julie, additional, Denning, David W., additional, Dennis, David T., additional, Dhanireddy, Shireesha, additional, Dielubanza, Elodi J., additional, Diemert, David J., additional, Doganay, Mehmet, additional, Doherty, Tom, additional, Dolecek, Christiane, additional, Dondorp, Arjen M., additional, Douglas, Abby, additional, Drancourt, Michel, additional, Dubourg, Grégory, additional, Dudley, Michael N., additional, Durand, Guillaume, additional, Eckhardt, Benjamin J., additional, Efstratiou, Androulla, additional, Ekkelenkamp, Miquel B., additional, Eranki, Ambika, additional, Erdem, Hakan, additional, Escota, Gerome V., additional, Evans, Heather L., additional, Eziefula, Alice Chijioke, additional, Fenollar, Florence, additional, Fenwick, Alan, additional, Fierer, Joshua, additional, Finch, Roger G., additional, Fleckenstein, James M., additional, Forstner, Christina, additional, Foschi, Federico, additional, Fournier, Pierre-Edouard, additional, French, Martyn A., additional, Gage, Kenneth L., additional, Garcia, Lynne S., additional, Gascon, Joaquim, additional, Gastañaduy, Arturo S., additional, Gautret, Philippe, additional, Geisler, William M., additional, Ghanem, Khalil G., additional, Giani, Tommaso, additional, Giannella, Maddalena, additional, Gilliam, Bruce L., additional, Gilliet, Michel, additional, Glaser, Carol A., additional, Glupczynski, Youri, additional, Gnann, John W., additional, Goldstein, Ellie J.C., additional, Gottstein, Bruno, additional, Gouriet, Frederique, additional, Gravitt, Patti E., additional, Green, Michael D., additional, Green, Stephen T., additional, Groll, Andreas H., additional, Gulick, Roy M., additional, Gupta, Arjun, additional, Habib, Gilbert, additional, Harbarth, Stephan, additional, Harris, Marianne, additional, Hayden, Frederick G., additional, Hetem, David J., additional, Hill, Philip C., additional, Hirschel, Bernard, additional, Hodowanec, Aimee C., additional, Hoffart, Louis, additional, Hoffmann, Christian, additional, Holland, Steven M., additional, Horby, Peter W., additional, Horne, David J., additional, Hraiech, Sami, additional, Hull, Mark W., additional, Huttner, Angela, additional, Ingram, Richard J.M., additional, Islam, Jasmin, additional, Ison, Michael G., additional, James, Scott H., additional, Jenkins, Claire, additional, Jenkins, Stephen G., additional, Jensen, Jørgen Skov, additional, Johnston, Christine, additional, Jones, Theodore B., additional, Jordan, Stephen J., additional, Julian, Kathleen G., additional, Kato, Yasuyuki, additional, Kauffman, Carol A., additional, Kaye, Keith S., additional, Keane, Michael P., additional, Keeney, James, additional, Kelly, Paul, additional, Kent, Stephen J., additional, Kern, Winfried V., additional, Keynan, Yoav, additional, Kim, Andrea A., additional, Koné-Paut, Isabelle, additional, Kosmidis, Chris, additional, Kroes, Aloys C.M., additional, Kroon, Frank P., additional, Ksiazek, Thomas G., additional, Kuhlmann, F. Matthew, additional, Kuijper, Ed J., additional, Kwon, Jennie H., additional, Kyei, George B., additional, Lacombe, Karine, additional, Lagacé-Wiens, Philippe, additional, Lagier, Jean-Christophe, additional, Lamagni, Theresa, additional, Landraud, Luce, additional, Lanternier, Fanny, additional, LaPlante, Kerry L., additional, Lawn, Stephen D., additional, Lawrence, Steven J., additional, Leblebicioglu, Hakan, additional, Lee, Nelson, additional, Leggett, James E., additional, Lehours, Philippe, additional, Levy, Pierre-Yves, additional, Leyh, Rainer G., additional, Lillis, Rebecca A., additional, Limmathurotsakul, Direk, additional, Lin, Jennifer, additional, Lindquist, H.D. Alan, additional, Lipsky, Benjamin A., additional, Liscynesky, Christina, additional, Looney, David, additional, Lortholary, Olivier, additional, Lowy, Franklin D., additional, Luft, Benjamin J., additional, Mackowiak, Philip A., additional, MacPherson, Paul A., additional, Maghraoui-Slim, Valérie, additional, Mallon, Patrick W., additional, Mangino, Julie E., additional, Manuel, Oriol, additional, Marchetti, Oscar, additional, Marks, Kristen M., additional, Marr, Kieren A., additional, Marrazzo, Jeanne, additional, Marschall, Jonas, additional, Martin, David H., additional, Matonti, Frédéric, additional, Matulewicz, Richard S., additional, Mayer, Kenneth H., additional, McCulloh, Russell J., additional, McGready, Rose, additional, Mdodo, Rennatus, additional, Mead, Simon, additional, Mégraud, Francis, additional, Meintjes, Graeme, additional, Metcalf, Sarah C., additional, Michaels, Marian G., additional, Migliori, Giovanni Battista, additional, Miles, Michael A., additional, Miller, Alastair, additional, Mimiaga, Matthew J., additional, Mingeot-Leclercq, Marie-Paule, additional, Misch, Elizabeth Ann, additional, Mitreva, Makedonka, additional, Montaner, Julio S.G., additional, Moore, Caroline B., additional, Muñoz, Patricia, additional, Muñoz, Jose, additional, Murray, Clinton K., additional, Musso, Didier, additional, Mutengo, Mable, additional, Mutizwa, Misha M., additional, Naber, Kurt G., additional, Natarajan, Pavithra, additional, Neme, Santiago, additional, Newton, Paul N., additional, Nichols, Ronald A., additional, Nicolle, Lindsay E., additional, Nosten, François, additional, Notarangelo, Luigi D., additional, Nutman, Thomas B., additional, Nyirjesy, Paul, additional, O'Connell, P. Ronan, additional, Opal, Steven M., additional, Ormerod, L. Peter, additional, Osmon, Douglas R., additional, Pankert, Marie Boulze, additional, Pantaleo, Giuseppe, additional, Papazian, Laurent, additional, Parente, Diane M., additional, Parola, Philippe, additional, Parsaei, Shadi, additional, Pascual, Manuel A., additional, Patel, Rupa, additional, Patrozou, Eleni, additional, Pawlotsky, Jean-Michel, additional, Peacock, Sharon J., additional, Pechère, Jean-Claude, additional, Pelegrin, Ivan, additional, Peters, Barry S., additional, Peters, Edgar J.G., additional, Petersen, Jeannine M., additional, Petersen, Lyle R., additional, Petraitis, Vidmantas, additional, Pham, Luu-Ly, additional, Picado, Albert, additional, Pilatz, Adrian, additional, Pilmis, Benoit, additional, Pinazo, María-Jesús, additional, Pletz, Mathias W., additional, Pogue, Jason M., additional, Polgreen, Evelyn L., additional, Polgreen, Philip M., additional, Posfay-Barbe, Klara M., additional, Powderly, William G., additional, Presti, Rachel, additional, Prod'hom, Guy, additional, Puolakkainen, Mirja, additional, Quinn, Thomas C., additional, Raoult, Didier, additional, Razonable, Raymund R., additional, Read, Robert C., additional, Redfield, Robert R., additional, Rentenaar, Rob J., additional, Reynolds, Steven J., additional, Ribi, Camillo, additional, Richardson, Malcolm D., additional, Ritter, Michele L., additional, Roch, Antoine, additional, Rockstroh, Jürgen Kurt, additional, Rojek, Amanda, additional, Romero, José R., additional, Rooijakkers, Suzan H.M., additional, Rosenbluth, Daniel, additional, Rosenzweig, Sergio D., additional, Rossolini, Gian Maria, additional, Rubinstein, Ethan, additional, Ryan, Greg, additional, Safren, Steven A., additional, Sahasrabuddhe, Vikrant V., additional, Saikku, Pekka A.I., additional, Sajadi, Mohammad M., additional, Salvaggio, Michelle R., additional, Santos, Carlos A.Q., additional, Satlin, Michael J., additional, Schaeffer, Anthony J., additional, Schimmer, Christoph, additional, Schooley, Robert T., additional, Schumacher, Richard F., additional, Sha, Beverly E., additional, Shapiro, Daniel S., additional, Sheehan, Gerard, additional, Shlaes, David M., additional, Shoham, Shmuel, additional, Simmons, Cameron P., additional, Simon, Dennis W., additional, Simon, Matthew S., additional, Simonsen, Kari A., additional, Slack, Mary P.E., additional, Smith, Tyrel T., additional, Sobel, Jack D., additional, Souli, Maria, additional, Sridhar, Shruti, additional, Steckelberg, James M., additional, Stevens, Dennis L., additional, Strah, Heather, additional, Sturm, A. Willem, additional, Sungkanuparph, Somnuek, additional, Tabrizi, Sarah J., additional, Tacconelli, Evelina, additional, Tan, Chen Sabrina, additional, Taplitz, Randy A., additional, Thomas, Guillemette, additional, Thomas, Lora D., additional, Thuny, Franck, additional, Thwaites, Guy, additional, Tissot, Frederic, additional, Tønjum, Tone, additional, Torriani, Francesca J., additional, Toso, Christian, additional, Tulkens, Paul M., additional, Tunkel, Allan R., additional, Turner, Claire E., additional, Ustianowski, Andrew P., additional, van Bambeke, Françoise, additional, van Crevel, Reinout, additional, van de Beek, Diederik, additional, van Delden, Christian, additional, van der Eerden, Menno M., additional, van der Meer, Jos W.M., additional, van der Poll, Tom, additional, van Ingen, Jakko, additional, van Putten, Jos, additional, Vaudaux, Bernard P., additional, Vermund, Sten H., additional, Viscidi, Raphael P., additional, Visvanathan, Kumar, additional, Visvesvara, Govinda S., additional, von Seidlein, Lorenz, additional, Wagenlehner, Florian M.E., additional, Wald, Anna, additional, Walsh, Thomas J., additional, Warhurst, David C., additional, Warnock, David W., additional, Warrell, David A., additional, Warrell, Mary J., additional, Warris, Adilia, additional, Watkins, Richard R., additional, Weatherall, David J., additional, Weber, Rainer, additional, Weidner, Wolfgang, additional, White, Jonathan R., additional, White, Peter J., additional, Whitehorn, James, additional, Whitley, Richard J., additional, Whitty, Christopher J.M., additional, Wiersinga, Willem Joost, additional, Wilcox, Mark H., additional, Williams, Thomas N., additional, Wilson, Cara C., additional, Wilson, Mary Elizabeth, additional, Wisplinghoff, Hilmar, additional, Wood, Robin, additional, Wunderink, Richard G., additional, Wyles, David, additional, Yang, Zhi-Tao, additional, Yoder, Jonathan S., additional, Zaidi, Najam A., additional, Zimmer, Andrea J., additional, Zuckerman, Jane N., additional, and Zumla, Alimuddin, additional

Published
2017
Full Text
View/download PDF

49. Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium.

Author

Nasreddine, Rakan, Florence, Eric, Yombi, Jean Cyr, Henrard, Sophie, Darcis, Gilles, Van Praet, Jens, Vandekerckhove, Linos, Allard, Sabine D., Demeester, Rémy, Messiaen, Peter, Ausselet, Nathalie, Delforge, Marc, and De Wit, Stéphane

Subjects
DRUG efficacy, HIV infections, ANTI-HIV agents, HIV-positive persons, COMBINATION drug therapy, DRUG tolerance, GENETIC mutation, VIRAL load, RETROSPECTIVE studies, DRUG resistance, TREATMENT effectiveness, DESCRIPTIVE statistics, RESEARCH funding, NUCLEOSIDE reverse transcriptase inhibitors
Abstract

Objectives: Our objective was to evaluate the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in a real‐world setting in Belgium. Methods: This was a retrospective, multicentre cohort study involving adult treatment‐naïve (TN) and treatment‐experienced (TE) people living with HIV receiving BIC/FTC/TAF between 1 January 2019 and 30 September 2020. The primary outcome was rate of virological suppression (plasma HIV‐1 viral load <50 copies/mL; on‐treatment analysis) at weeks 24 and 48. The main secondary outcomes included loss of virological suppression (LVS; two consecutive viral loads of >200 copies/mL after being virologically suppressed) by week 48 and analysis of resistance‐associated mutations at time of LVS; tolerability of BIC/FTC/TAF over the 48‐week study period; and change in weight and proportion of participants reporting a >10% weight gain at week 48. Results: Overall, 2001 participants were included. Through 48 weeks, overall rate of virological suppression was 93.5%, with similar results observed in the following subgroups: age ≥50 years (92.7%), women (92.8%), Black sub‐Saharan African (91%), TN (94%), TE (93.2%), and non‐suppressed at baseline (86.6%). LVS was observed in 0.7% (n = 14) of participants, with one participant developing resistance‐associated mutations to nucleoside reverse transcriptase inhibitors (184 V) and integrase strand transfer inhibitors (263KR). Of the 131 (6.5%) treatment discontinuations, the most common reason was an adverse event (2.4%), with the most frequent being central nervous system/psychiatric (0.4%) and gastrointestinal (0.4%) toxicity. Median weight gain at week 48 was 2 kg (interquartile range −1 to 5), and a >10% weight increase was observed in 11.6% of participants. Conclusion: In this large real‐world cohort, BIC/FTC/TAF showed excellent virological efficacy in a diverse population of patients with HIV. Rare occurrence of emergent drug resistance was observed, and treatment was well tolerated. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results